Last reviewed · How we verify
13vPnC (13vpnc)
At a glance
| Generic name | 13vpnc |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Vaccine |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain (PAIN)
- Myalgia (MUSCLE PAIN)
- Fatigue
- Fatigue (FATIGUE)
- Headache
- Arthralgia (JOINT PAIN)
- Headache (HEADACHE)
- Injection site swelling (SWELLING)
- Injection site erythema (REDNESS)
- Pain (Any)
- Pain (Mild)
- New generalized muscle pain
Key clinical trials
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (PHASE3)
- A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children (PHASE3)
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan (PHASE3)
- Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 (PHASE3)
- A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |